Synonymer & Information om | Engelska ordet MYELOFIBROSIS

Exempel på hur man kan använda MYELOFIBROSIS i en mening

• It has been associated with chemotherapy, radiation therapy, myelofibrosis, aplastic anemia (failure of white cell, red cell and platelet production), stem cell transplant, bone marrow transplant, HIV, AIDS, and steroid use.
• HCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s.
• Imetelstat is currently in two Phase 3 trials: NCT02598661, a study of the drug's ability to reduce the transfusion requirements of patients with myelodysplastic syndrome (MDS), and NCT04576156, an investigation of the drug's effect on the overall survival of patients with myelofibrosis.
• In January 2018, Celgene announced it would acquire Impact Biomedicines for $7 billion, adding fedratinib, a kinase inhibitor with potential to treat myelofibrosis.
• Some examples of this would include chronic cancers with liver metastases, infiltrative haematological disorders such as chronic lymphoproliferative conditions, chronic myeloid leukaemias, myelofibrosis and metabolic abnormalities such as Gaucher's disease and glycogen storage diseases.
• Myeloproliferative neoplasms including polycythemia vera, essential thrombocythemia, primary myelofibrosis, chronic neutrophilic leukemia , and chronic eosinophilic leukemia.
• Mutations in JAK2 have been implicated in polycythemia vera, essential thrombocythemia, and myelofibrosis as well as other myeloproliferative disorders.
• Elevation of basophils may also be representative of multiple other underlying neoplasms such as polycythemia vera (PV), myelofibrosis, thrombocythemia, or, in rare cases, solid tumors.
• Bone biopsy shows abnormal megakaryocytes, macrocytic erythropoiesis, and defects in neutrophil production and fibrosis of the marrow (myelofibrosis).
• These tear drop cells are found primarily in diseases with bone marrow fibrosis, such as: primary myelofibrosis, myelodysplastic syndromes during the late course of the disease, rare form of acute leukemias and myelophthisis caused by metastatic cancers.
• Several successful regulatory approvals have used ePRO data in recent years, including ketorolac for ocular pain, eszopiclone for insomnia, milnacipran for fibromyalgia, estradiol/levonorgestrel for post-menopausal symptoms, and ruxolitinib for myelofibrosis.
• In the United States and the European Union, ruxolitinib is indicated for the treatment of disease-related splenomegaly or symptoms in adults with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythaemia-vera myelofibrosis, or post-essential thrombocythaemia myelofibrosis.
• Several Phase II clinical trials were completed that investigated use of obatoclax in the treatment of leukemia, lymphoma, myelofibrosis, and mastocytosis.
• Fedratinib, sold under the brand name Inrebic, is an anti-cancer medication used to treat myeloproliferative diseases including myelofibrosis.
• Kinard suffered from myelofibrosis, a disease in which bone marrow cells become abnormal and create collagenous connective tissue fibers rather than new bone marrow.
• The company's portfolio also includes GB1211, an orally delivered galectin-3 inhibitor, for the treatment of systemic fibrotic diseases, including liver cirrhosis; and GB2064, an inhibitor of lysyl oxidase like 2, or LOXL2, an enzyme directly involved in formation of fibrosis which was part of the company's plan to develop in myelofibrosis.
• Possible pathologic causes include anemia, myelofibrosis, thalassemia, miliary tuberculosis, cancers involving bone marrow (myelomas, leukemias, lymphomas), and in chronic hypoxemia.
• Malignancies and/or premalignant hematologic conditions not due to a primary disorder in eosinophils such as Gleich's syndrome, Lymphocyte-variant hypereosinophilia Hodgkin disease, certain T-cell lymphomas, acute myeloid leukemia, the myelodysplastic syndromes, systemic mastocytosis, chronic myeloid leukemia, polycythemia vera, essential thrombocythemia, myelofibrosis, chronic myelomonocytic leukemia, and T-lymphoblastic leukemia/lymphoma-associated or myelodysplastic–myeloproliferative syndrome-associated eosinophilias; IgG4-related disease and Angiolymphoid hyperplasia with eosinophilia as well as non-hematologic cancers such as solid tumors of the lung, gastrointestinal tract, and genitourinary tract.
• A phase II trial is underway for patients with myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, or myelofibrosis, who had failed ruxolitinib.
• iMCD patients with thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly syndrome (TAFRO syndrome) are considered to have a distinct clinical subtype of iMCD.

Förberedelsen av sidan tog: 131,15 ms.